NCT00417222View on ClinicalTrials.gov

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

PHASE3CompletedINTERVENTIONAL

Enrollment

1,145

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2013

Study Completion Date

December 31, 2013

Conditions

Chronic Heart Failure

Interventions

DRUG

olmesartan medoxomil

5 to 40mg P.O. daily until the end of the study

Trial Locations (1)

980-8574

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai

All Listed Sponsors

lead

Tohoku University

OTHER

NCT00417222 - Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan | Biotech Hunter | Biotech Hunter